Clinical trial
Rituximab in Treating Patients With Hodgkin's Lymphoma
NCT00003820 · Ranjana Advani, Other · Completed
Key facts
| NCT number | NCT00003820 |
|---|---|
| Title | Rituximab in Treating Patients With Hodgkin's Lymphoma |
| Official title | Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease |
| Lead sponsor | Ranjana Advani, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Hodgkin Lymphoma (Category), Nodular Lymphocyte Predominant Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 39 |
| Start date | Jan 1, 1999 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: